– Histological specimens from 95 RCCs were immunostained for p53 protein, E-cadherin and Ki-67 antigen. Results, as well as stage and grade, were correlated to overall survival and disease-free interval. Markers were also correlated to each other. Statistically significant correlations were observed between stage, grade and Ki-67 versus both overall survival and disease-free interval and between Ki-67 and grade. The authors conclude that the analysis of cell proliferation by Ki-67 immunostaining may help improve understanding of the RCC prognosis.
MonicaB., MinariR.: Indici di proliferazione (Ki-67, TLI) ed espressione della p53. Esperienza personale. Urologia, 62 (2): 234–9, 1995.
2.
SoiniY., Turpeenniemi-HujuanenT., KamelD., Autio-HarmainenH., RisteliH., RisteliL., NuorvaK., PääkköP., VähäkangasK: p53 immunohistochemistry in transitional cell carcinoma and dysplasia of the urinary bladder correlates with disease progression. Br. J. Cancer, 68: 1029–35, 1993.
3.
Van den BergF.M., TiggesA.J., SchipperM.E.I., den Hartog-JagerF.C.A., KroesW.G.M., WalboomersJ.M.M.: Expression of the nuclear oncogene p53 in colon tumours. J. Pathol. (Lond.), 157: 193–9, 1989.
deRieseW.T.W., CrabtreeW.N., AllhoffE.P., WernerM., LiedkeS., LenisG., AtzpodienJ., KirchnerH.: Prognostic significance of Ki-67 immunostaining in nonnmetastatic renal cell carcinoma. J. Clin. Oncol., 11: 1804–08, 1993.
6.
SaracinoG.A., DitonnoP., BattagliaM., MartinoP., IacobellisM., GiardinaC., ZizziV., ParadisoA., BarlettaA., SelvaggiF.P.: Does p53 protein and flow cytometry predict clinical outcome in renal cell carcinoma?Eur. Ur., 30, (S2): 216, 1996.
7.
UhlmanD.L., NguyenP.L., ManivelJ.C., AeppliD., ResaickJ.M., FraleyE.E., ZhangG., NiehansG.: Association of immunohistochemical staining for p53 with metastatic progression and poor survival in patients with renal cell carcinoma. J. Natl. Can. Inst., 86 (19): 1470–5, 1994.
8.
BotF.J., GodschalkJ.C.J., KrishnadathK.K., van der KwastT.H.M., BosmanF.: Prognostic factors in renal cell carcinoma: immunohistochemical detection of p53 protein versus clinico-pathological parameters. Int. J. Cancer, 57: 634–7, 1994.
9.
AnglardP., ToryK., BrauchH., WeissG.H., LatifF., MerinoM.J., LermanM.I., ZbarB., LinehanW.M.: Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res., 51: 1071–7, 1991.
10.
ReiterE., AnglardP., LiuS., GnarraJ.R., LinehanW.M.: Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res., 53: 3092–7, 1993.
11.
ChemerisG., LoktinovA., RempelA., SchwartzM., BannaschP.: Elevated content of p53 protein in absence of p53 gene mutation as a possible marker for human renal cell tumours. Virchows Arch., 426: 563–9, 1995.
12.
KatagiriA., WatanabeR., TornitaY.: E-cadherin expression in renal cell cancer and its significance in metastases and survival. Br. J. Cancer, 71: 376–9, 1995.
13.
ShimazuiT., BringuierP.P., GiroldiL., OosterwijkE., DebruyneF.M.J., SchalkenJ.A.: Identification and characterization of cadherin-catenin complexes in renal cell carcinoma cell line. J. Urol., 155 (suppl.): 344A, 135, 1996.
